Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Status:	Recruiting
Conditions:	Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	1/17/2019
Start Date:	May 14, 2013
End Date:	May 12, 2023
Contact:	Novartis Pharmaceuticals
Phone:	1-888-669-6682

An Open-label, Multi-center Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study and Are Judged by the Investigator to Benefit From Continued Everolimus Treatment

Study to allow access to everolimus for patients who are on everolimus treatment in a
Novartis-sponsored study and are benefiting from the treatment as judged by the investigator

Inclusion Criteria:

- Patient is currently enrolled in a Novartis-sponsored, CD&MA study receiving
everolimus or everolimus plus Sandostatin LAR Depot and has fulfilled all their
requirements in the parent study

- Patient is currently benefiting from treatment with everolimus, as determined by the
guidelines of the parent protocol.

Exclusion Criteria:

- Patient has been permanently discontinued from everolimus study treatment in the
parent study.

- Patient is receiving everolimus in combination with an unapproved or experimental
treatment

- Other protocol-defined inclusion/exclusion criteria may apply

We found this trial at

sites

Nebraska Cancer Specialists Onc Dept

Omaha, Nebraska 68154

Principal Investigator: Ralph Hauke

Phone: 402-691-6972

from

Omaha, NE